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Abstract 
Background: Research on germline genetic variants relies on enough eligible participants which is difficult to 
achieve for rare diseases such as childhood cancer. With self-collection kits, participants can contribute genetic 
samples conveniently from their home. Demographic and clinical factors were identified previously that influenced 
participation in mailed self-collection. People with pre-existing heritable diagnoses might participate differently in 
germline DNA collection which might render sampling biased in this group. In this nationwide cross-sectional study, 
we analysed predictive factors of participation in DNA self-collection including heritable diagnoses.
Methods: We identified childhood cancer survivors from the Swiss Childhood Cancer Registry for invitation to 
germline DNA self-sampling in September 2019. Participants received saliva sampling kits by postal mail at their 
home, were asked to fill them, sign an informed consent, and send them back by mail. Two reminders were sent to 
non-participants by mail. We compared demographic, clinical, and treatment information of participants with non-
participants using univariable and multivariable logistic regression models.
Results: We invited 928 childhood cancer survivors in Switzerland with a median age of 26.5 years (interquartile 
range 19-37), of which 463 (50%) participated. After the initial send out of the sampling kit, 291 (63%) had par-
ticipated, while reminder letters led to 172 additional participants (37%). Foreign nationality (odds ratio [OR] 0.5; 
95%-confidence interval [CI] 0.4-0.7), survivors aged 30-39 years at study versus other age groups (OR 0.5; CI 0.4-0.8), 
and survivors with a known cancer predisposition syndrome (OR 0.5; CI 0.3-1.0) were less likely to participate in 
germline DNA collection. Survivors with a second primary neoplasm (OR 1.9; CI 1.0-3.8) or those living in a French or 
Italian speaking region (OR 1.3; CI 1.0-1.8) tended to participate more.
Conclusions: We showed that half of childhood cancer survivors participated in germline DNA self-sampling relying 
completely on mailing of sample kits. Written reminders increased the response by about one third. More targeted 
recruitment strategies may be advocated for people of foreign nationality, aged 30-39 years, and those with cancer 
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Background
Cancer survivorship and associated health complica-
tions have become increasingly important with improved 
childhood cancer survival [1]. Chronic conditions like 
cardiac, pulmonary, auditory, endocrine, reproductive, 
and neurocognitive complications, and second primary 
neoplasms (SPNs) are gaining importance in research 
and clinical care [2]. By age 50 years, childhood cancer 
survivors have twice as many severe chronic health con-
ditions compared to controls [3]. Mortality in survivors 
is more than 10-times higher than in the general popu-
lation [4]. While many demographic, clinical, and treat-
ment-related risk factors are known, the contribution of 
genetic variation in the development of health complica-
tions is still poorly understood [5–7].
Self-sampling of germline DNA by participants has 
increased the reach of sample collection particularly in 
target groups who do not attend regular medical care. 
Since the 1990’s buccal swabs are used. In the 2010’s 
saliva collection kits became widely available which are 
easy to use and yield DNA of good quality and sufficient 
quantity [8]. Saliva collection kits do not need time-sensi-
tive processing or cooling like blood, but can be collected, 
transported, and stored in ambient conditions for years. 
Collection of saliva samples by participants themselves is 
feasible and effective [5]. Self-collection may, however, be 
affected by participation bias. Ness et al. identified female 
sex, white race/ethnicity, college graduation, never smok-
ing, accessing the healthcare system in the past 2 years, 
and having a second malignant neoplasm as predictors 
for participating in saliva sample self-collection [5]. Out-
side of the US, predictors for participation in childhood 
cancer survivors have not been studied. Demographic 
and cultural differences might affect the perception of 
the healthcare system and acceptance of genetic research 
and lead to lower participation in some subgroups [9, 
10]. Patients with heritable diagnoses underwent previ-
ous genetic workup and might therefore differ in their 
perception of genetic research compared to patients 
without known heritable diagnoses. Their willingness 
of participation in genetic research might differ which 
subsequently affects their inclusion in research. Herit-
able diagnoses have not been included in studies on DNA 
self-sampling, previously. We assessed the response rate 
over time, the influence of written reminders, and predic-
tors for participation in DNA self-sampling in Switzer-
land as part of the national Germline DNA Biobanking 




For this cross-sectional study, we used contact informa-
tion from the Swiss Childhood Cancer Registry (SCCR) 
at the Institute of Social and Preventive Medicine, Uni-
versity of Bern, Switzerland to invite childhood cancer 
survivors for germline DNA self-collection. Addresses 
were collected from hospitals involved in primary and 
follow-up care and updated through the Swiss national 
postal service.
We obtained data on patient characteristics from the 
SCCR. In September 2019, participants received self-
sampling kits by postal mail at their home and were asked 
to send them to the germline DNA Biobank Switzerland 
for Childhood Cancer and Blood Disorders (BISKIDS), 
which is part of the Paediatric Biobank for Research in 
Haematology and Oncology (BaHOP) Geneva, Switzer-
land. All participants received an informed consent form 
together with the saliva kit. BaHOP was awarded the 
VITA label which certifies compliance of applicable ethi-
cal and legal frameworks and appropriate governance to 
biobanks by the Swiss Biobanking Platform (SBP; www. 
bioba nksqan. ch/#/ bioba nks/ 3919). The SBP is the Swiss 
national coordination platform for human and non-
human biobanks initiated by the Swiss National Science 
Foundation (https:// swiss bioba nking. ch). The Geneva 
Cantonal Commission for Research Ethics has approved 
the BaHOP biobank (approval PB_2017-00533) and the 
associated “Genetic Risks for Childhood Cancer Compli-
cations Switzerland (GECCOS)” study, which will utilize 
the samples (approval 2020-01723). We followed the rec-
ommendations of the STROBE statement to report the 
findings of our study (Supplementary Table 1).
Study population
Eligible for invitation to our study were participants 
who were: (i) registered in SCCR; (ii) Swiss residents; 
(iii) treated in one of nine paediatric hospitals caring for 
predisposition syndromes. Perceptions of genetic research and potential barriers to participation of survivors need to 
be better understood.
Trial registration: Biobank: https:// direc tory. bbmri- eric. eu/#/ colle ction/ bbmri- eric: ID: CH_ Hopit auxUn ivers itair esGen 
eve: colle ction: CH_ BaHOP Resea rch proje ct: Clinicaltrials.gov: NCT04 702321.
Keywords: Childhood cancer, Cancer survivors, DNA, Cohort study, Drug side effects, Second primary neoplasm, 
Genetic predisposition, Registry, Genetic testing, Genetic polymorphism
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children with cancers; (iv) diagnosed with a neoplasm 
according to the International Classification of Child-
hood Cancers, 3rd edition (ICCC-3), or Langerhans cell 
histiocytosis before age 21 years from 1976 to 2017; (v) 
exposed to lung toxic (chest radiotherapy) or ototoxic 
treatment (brain radiotherapy with ≥30 Gray or plati-
num chemotherapy); and (vi) survivors of 2 years or more 
since childhood cancer diagnosis as of July 2019 without 
upper age limit. We excluded participants who: (I) had 
declined participation in research projects; (II) had died; 
or (III) did not have a valid address in Switzerland.
Outcome definition and clinical characteristics
Our main outcome was participation in the germline 
DNA sample collection, defined as returning the DNA 
sample and the signed consent form. Non-participa-
tion was defined as active decline or non-response until 
December 2020 (end of follow-up). Clinical informa-
tion was extracted from the SCCR. We classified the age 
at first neoplasm in 5-year groups, calendar year at first 
neoplasm diagnosis and age at survey in 10-year groups, 
and the first neoplasm diagnoses into ICCC-3 main cat-
egories [11]. Chemotherapy, radiotherapy, and haemat-
opoietic stem cell transplantation were classified as “yes” 
if given during the first neoplasm treatment. We classi-
fied cancer predisposition syndromes (CPSs) and second 
primary neoplasms (SPNs) as previously described [12]. 
In brief, we assigned underlying diseases as CPSs if they 
were reported in the current literature to be associated 
with an increased relative risk of neoplasms compared to 
the general population and SPNs according to the defini-
tions of the International Agency for Research on Cancer.
Sample collection
Survivors received  a letter by postal mail with informa-
tion on the planned DNA sample collection, and a form 
with which they could opt out and a prepaid return enve-
lope. Those who did not opt out received 3 weeks later a 
parcel including (i) detailed information on the biobank-
ing project and an informed consent form to sign, (ii) one 
Oragene DNA OG-500 saliva sampling kit (manufac-
tured by DNA Genotek, Ottawa, Ontario, Canada) with 
material for return by regular mail (liquid-tight bio-spec-
imen bag, bubble wrap), (iii) information on saliva sample 
collection and shipment provided by the manufacturer 
(www. dnage notek. com/ row/ produ cts/ colle ction- human/ 
orage ne- dna/ 500- series/ OG- 500. html), (iv) a graphical 
abstract of the workflow of saliva collection and return of 
samples and consent forms, and (v) prepaid return enve-
lopes for return of the consent form and the saliva sam-
ple. We sent two letters as reminders to those who did 
not return the sample, one after 6 weeks and another one 
after 8 weeks.
We offered participants the opportunity to receive addi-
tional information through (i) a project specific e-mail 
address, and (ii) a dedicated telephone hotline. Both were 
operated by the study coordinator, a trained specialist in 
paediatric haematology and oncology with experience in 
cancer genetics, or biobank staff in case of absence.
Statistical analysis
We compared demographic, neoplasm, treatment, 
relapse, second neoplasm, and predisposition syndrome 
information of participants with non-participants. Uni-
variable logistic regression and multivariable logistic 
regression models were fitted to identify determinants 
of participation. Covariates were kept in the multivari-
able logistic regression model using backward selection. 
We removed covariates with p ≥ 0.2. We additionally 
adjusted for sex and age at first primary neoplasm diag-
nosis in the model. We used the software Stata version 15 
(Stata Corporation, Austin, Texas) for analyses. Statisti-




We traced and contacted 928 of 1215 eligible childhood 
cancer survivors (Fig.  1). Of those we contacted, 463 
(50%) returned a germline DNA sample. Median age at 
diagnosis was 8.7 years (interquartile range [IQR] 3-13) 
and at invitation 26.5 years (IQR 19-37; Table 1). The most 
common diagnoses were central nervous system tumours 
(28%) and lymphomas (20%) which reflected our selection 
process of inviting former childhood cancer patients with 
pulmotoxic and ototoxic treatments. Most patients had 
been treated with chemotherapy (93%) and radiotherapy 
(66%), while a minority underwent haematopoietic stem 
cell transplantation (7%). Relapse had been confirmed in 
20% of survivors, a second primary neoplasm in 4% and 
a cancer predisposition syndrome (CPS) in 5%. Survivors 
were predominantly from the German (n = 633; 68%) lan-
guage region and the remaining from the French (n = 262; 
28%) and Italian (33; 4%) language region, which roughly 
reflects the language distribution in Switzerland.
Recruitment and impact of reminders
We invited 928 survivors for home saliva collec-
tion. After the first information letter, 64 (7%) actively 
declined participation through an opt-out reply form. 
The remaining 864 survivors received a saliva sampling 
kit and an informed consent form. Seventy-seven of 
those actively refused participation (8%) and 324 eligi-
ble survivors did not answer (35%). Within 6 weeks after 
the send out of the sampling kit, 291 (63%) participated 
(Fig.  2). The first reminder letter led to 117 additional 
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participants (25%) and the second reminder to an addi-
tional 55 participants (12%). On the consent form, 383 
(83%) indicated that they wanted to be informed about 
potential incidental findings and 394 (85%) agreed that 
their samples could be used after death. Only a small 
proportion of invited people used the phone hotline 
(n = 32) or the e-mail contact provided (n = 31).
Covariates associated with participation
We identified demographic and clinical covariates that 
differed between participants and non-participants. 
Foreign nationality (odds ratio [OR] 0.5; 95%-con-
fidence interval [CI] 0.4-0.7) and age at study were 
associated with non-participation. Survivors aged 
30-39 years at study invitation participated least (OR 
0.5; CI 0.4-0.8), those 10-29 years tended to participate 
best, and those < 10 years and > 40 years in between. 
Those with a cancer predisposition syndrome tended 
to participate less (OR 0.5; CI 0.3-1.0), while survi-
vors with a diagnosis of a second primary neoplasm 
(OR 1.9; CI 1.0-3.8) and those who spoke French or 
Italian (OR 1.3; CI 1.0-1.8) tended to participate more. 
There were no differences in sex, age at first primary 
neoplasm diagnosis, diagnostic groups, treatments, 
and relapse of first primary neoplasm between partici-
pants and non-participants.
Fig. 1 Flowchart of the response to invitation to the BISKIDS home collection of germline DNA in 928 cancer survivors. Legend: ICCC-3, 
international classification of childhood cancer, edition 3; n, number
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Table 1 Characteristics of 928 Swiss childhood cancer survivors invited to home collection of germline DNA, stratified by participation 
status




Characteristic Total (n; %)a Yes (n; %)a No (n; %)a OR (95%-CI) p-value OR (95%-CI) p-value
Sex
Female 426 (46) 209 (45) 217 (47) Ref. Ref.
Male 502 (54) 254 (55) 248 (53) 1.06 (0.82 - 1.38) 0.64 1.09 (0.83-1.42) 0.53
Nationality
Swiss 710 (76) 377 (81) 333 (72) Ref. Ref.
Foreign 218 (24) 86 (19) 132 (28) 0.58 (0.42-0.78) < 0.001 0.53 (0.38-0.73) < 0.001
Correspondence language
German 633 (68) 308 (67) 325 (70) Ref. Ref.
French and Italian 295 (32) 155 (33) 140 (30) 1.17 (0.89-1.54) 0.27 1.31 (0.98-1.75) 0.07
Age at first neoplasm diagnosis
Median (IQR; years) 8.7 (3.0-13.4) 8.7 (3.0-13.4) 8.6 (3.6-13.3)
0-4 years 311 (33) 166 (36) 145 (31) 1.14 (0.83 – 1.57) 0.35 1.08 (0.75-1.56) 0.4
5-9 years 212 (23) 97 (21) 115 (25) 0.84 (0.59 - 1.20) 0.79 (0.54-1.14)
10-14 years 287 (31) 144 (31) 143 (31) Ref. Ref.
15-20 years 118 (13) 56 (12) 62 (13) 0.90 (0.58 - 1.38) 0.95 (0.61-1.48)
Year of diagnosis
1976-1985 110 (12) 54 (12) 56 (12) 0.84 (0.55 - 1.30) 0.02 ‡
1986-1995 193 (21) 78 (17) 115 (25) 0.59 (0.41 - 0.85) ‡
1996-2005 312 (33) 164 (35) 148 (32) 0.97 (0.71 - 1.33) ‡
2006-2016 313 (34) 167 (36) 146 (31) Ref. ‡
Diagnostic group of first primary neoplasm (ICCC-3)
Leukaemias, myeloproliferative and myelo-
dysplastic diseases
35 (4) 14 (3) 21 (5) 0.77 (0.37-1.58) 0.38
Lymphomas 190 (20) 95 (21) 95 (20) 1.15 (0.79-1.68)
CNS tumours and miscellaneous intracra-
nial and intraspinal neoplasms
256 (28) 119 (26) 137 (29) Ref.
Neuroblastoma and other peripheral nerv-
ous cell tumours
78 (8) 45 (10) 33 (7) 1.57 (0.94-2.62)
Retinoblastoma 44 (5) 18 (4) 26 (6) 0.8 (0.42-1.53)
Renal tumours 33 (4) 20 (4) 13 (3) 1.77 (0.85-3.71)
Hepatic tumours 24 (2) 15 (3) 9 (2) 1.92 (0.81-4.54)
Malignant bone tumours 100 (11) 56 (12) 44 (9) 1.47 (0.92-2.33)
Soft tissue and other extraosseous sarco-
mas
94 (10) 48 (10) 46 (10) 1.2 (0.75-1.93)
Germ cell tumours, trophoblastic tumours, 
and neoplasms of gonads
64 (7) 29 (6) 35 (8) 0.95 (0.55-1.65)
Other malignant epithelial neoplasms and 
malignant melanomas
6 (< 1) 2 (< 1) 4 (< 1) 0.58 (0.1-3.2)
Langerhans cell histiocytosis 4 (< 1) 2 (< 1) 2 (< 1) 1.15 (0.16-8.3)
Chemotherapy
No 61 (7) 25 (5) 36 (8) Ref.
Yes 867 (93) 438 (95) 429 (92) 1.47 (0.87-2.49) 0.15
- With platinum agents 491 (53) 259 (56) 232 (50) 1.27 (0.98-1.64) 0.07
Radiotherapy
No 319 (34) 160 (35) 159 (34) Ref.
Yes 609 (66) 303 (65) 306 (66) 0.98 (0.75-1.29) 0.91
- With head radiotherapy (≥30 Gy) 343 (37) 166 (36) 177 (38) 0.91 (0.70-1.19) 0.49
- With chest radiotherapy 328 (35) 156 (34) 172 (37) 0.87 (0.66-1.33) 0.29
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Discussion
This study described participation of Swiss childhood 
cancer survivors in home saliva collection for germline 
DNA extraction. We confirmed previous findings of 
about 50% participation in home DNA self-collection. 
Foreign nationality was a strong predictor for non-partic-
ipation. Survivors with known CPSs and aged 30-39 years 
were also less likely to participate. In contrast, survivors 
with second primary neoplasms were more likely to 
participate. Most participating survivors wanted to be 
Table 1 (continued)




Characteristic Total (n; %)a Yes (n; %)a No (n; %)a OR (95%-CI) p-value OR (95%-CI) p-value
Haematopoietic stem cell transplantation
No 864 (93) 428 (92) 436 (94) Ref.
Yes 64 (7) 35 (8) 29 (6) 1.23 (0.74-2.05) 0.43
Relapse of first neoplasm
No 738 (80) 368 (79) 370 (80) Ref.
Yes 190 (20) 95 (21) 95 (20) 1.01 (0.73-1.38) 0.97
Cancer predisposition syndrome
No 879 (95) 442 (95) 437 (94) Ref. Ref.
Yes 49 (5) 21 (5) 28 (6) 0.74 (0.42-1.33) 0.31 0.54 (0.29-1.0) 0.05
Second primary neoplasm
No 889 (96) 438 (95) 451 (97) Ref. Ref.
Yes 39 (4) 25 (5) 14 (3) 1.84 (0.94-3.58) 0.07 1.92 (0.97-3.82) 0.06
Age at study invitation
Median (IQR; years) 26.5 (18.8-36.5) 25.1 (18.3-35.2) 27.7 (19.5-37.3)
< 10 years 50 (6) 23 (5) 27 (6) 0.72 (0.4-1.32) 0.005 0.75 (0.39-1.43) 0.002
10-19 years 215 (23) 121 (26) 94 (20) 1.09 (0.77-1.56) 1.17 (0.81-1.70)
20-29 years 296 (32) 160 (35) 136 (29) Ref. Ref.
30-39 years 198 (21) 78 (17) 120 (26) 0.55 (0.38-0.8) 0.54 (0.38-0.79)
40 or more years 169 (18) 81 (17) 88 (19) 0.78 (0.54-1.14) 0.72 (0.48-1.07)
Legend: ‡, omitted from multivariable regression model for collinearity with age at study invitation; a, column percentages are indicated; CNS central nervous system, 
ICCC-3 international classification of childhood cancer, edition 3; IQR interquartile range; n, number
Fig. 2 Recruitment over time of Swiss childhood cancer survivors invited for home germline DNA collection. Legend: n, number; W, week
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informed about incidental findings that might be relevant 
to their health and most agreed to their samples being 
available for research after their death.
The overall response rate of 50% was comparable to 
other DNA sample self-collections from home. Ness et al. 
reported 54% participation on 10,356 eligible adult child-
hood cancer survivors [5] and Dykema found 54% par-
ticipation in 8081 adults in the Wisconsin Longitudinal 
Study [13]. Nishita et  al. offered an incentive of 25US$ 
for returning a saliva sample which led to 59% partici-
pation of 967 adults in a smoking cessation trial, which 
was slightly higher than in studies without incentive [14]. 
Lower participation was found in genetic assessment of 
preterm birth where 23% of 708 mothers participated 
[15]. This study used an opt in approach where invited 
mothers were asked to reply by email, phone, text, or 
postal mail to indicate their interest in participating and 
then were sent DNA sampling kits. In contrast, we used 
a first letter explaining the study and giving the opportu-
nity to indicate refusal of participation. All eligible peo-
ple who did not opt out were then sent the sampling kit 
which might explain higher participation in our study. 
Even higher participation rates were achieved in an 
active clinical setting with patient-caregiver interaction 
where 97% of 155 adults from the US participated [16]. 
The close interaction of caregivers with participants and 
the possibility to address questions directly at invitation 
might have increased willingness to participate in the lat-
ter setting.
Foreign nationality was strongly associated with non-
participation in concordance with a previous study from 
our group on response to questionnaire studies [17]. This 
could be related to language issues affecting understand-
ing or reluctance to participate in research due to lower 
confidence in research. Foreign nationality is also linked 
to lower socioeconomic status, which was a predictor 
for lower participation in research [10]. Only few people 
used the provided phone or e-mail for further informa-
tion. We did not differentiate the nationality in those who 
sought contact. Easy to understand information mate-
rial, maybe in more languages, and invitation by phone 
might counteract these differences in participation. Our 
findings on language difference were in contrast to a large 
Swiss survey on willingness to participate in personal-
ized health research [10], and our group’s previous pub-
lication on participation in a questionnaire study [17], 
where German speaking people were more likely to par-
ticipate. The former was sent from the previously treat-
ing institutions and the latter from a German speaking 
research institution. In our study, the invitation was sent 
off from Geneva hospital, situated in the French speak-
ing language region, which might have improved accept-
ance of the study of the people living in this language 
region. Survivors with known CPSs were less willing to 
participate in our study. Reasons could be the impression 
of futility as participants were already genetically inves-
tigated, fear of further findings, or bad experiences with 
genetic workup. Survivors with second primary neo-
plasms tended to participate more, potentially because 
they were seeking explanations for their multiple neo-
plasms. Lower participation in older survivors might be 
reflective of being more distanced to the previous disease 
or in a busy phase of their lives (caring for children and 
being active at work).
The approximate costs for preparation, sending out the 
samples, and for the send back by participants were simi-
lar to the price for the sampling kits themselves (around 
20 Euros) and therefore doubled the costs per invited 
participant (around 40 Euros). The advantages of saliva 
samples are the ease of use (non-invasive collection), 
which is particularly relevant for paediatric populations, 
the reach of participants who do not attend regular medi-
cal care or who do not want to come to a hospital to par-
ticipate in the study, and the possibility to store them at 
room temperature for years. While other germline DNA 
sampling techniques such as blood draws might be rela-
tively inexpensive, the need for healthcare professionals 
to get the samples, quick processing or shipping, and cold 
storage, made saliva sampling kits cost-effective in previ-
ous studies [18].
More than 80% of participants wanted to be informed 
of incidental findings relevant to their health and agreed 
on further use of their samples after death. Our find-
ings are in line with a previous study on the preference 
on information of incidental findings in genetic research 
[19]. A systematic review showed a high proportion 
of research participants who agreed on further use of 
genetic samples after the participant’s death [20]. There is 
still a minority who does not want to be informed of inci-
dental findings or disagrees with use after death. In the 
setup of our biobank, we will account for these wishes.
A limitation of our study was that people who have 
died before study start could therefore not contribute 
DNA. We further did not collect information on reasons 
for non-participation. We also did not send additional 
sampling kits with reminders which might have pre-
vented survivors from participating who had discarded 
their kit already. Strengths of the study were the availabil-
ity of clinical information including CPSs. Our results of 
the study are likely representative for childhood cancer 
survivors in other countries with similar trust in health-
care institutions and responsible (genetic) research.
There are several areas that might be further investi-
gated in future research to potentially improve participa-
tion. The optimal timing of reminders in mail-based study 
invitations has not been identified to our knowledge. 
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We sent reminders out 6 weeks after the invitation and 
another 8 weeks after the first reminder, but shorter 
intervals could be tested. Phone reminders, a larger selec-
tion of languages, and possibly targeted invitation mate-
rial for specific subgroups illustrating the importance of 
their contribution could also improve participation.
Conclusion
Our study illustrates that home saliva collection through 
a process completely relying on mail is feasible and yields 
a response rate of about 50%. Specific survivor groups 
(foreign nationality, age 30-39 years, and patients with 
cancer predisposition syndromes) were less likely to par-
ticipate which needs to be taken into account when stud-
ies are planned.
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